Cancer Research

{
  "result": " This tick marks a sharp pivot from diffuse clinical literature toward foundational, hypothesis-driven architecture in colorectal cancer biology. Rather than treating CRC as a single disease, the swarm began mapping two targeted axes—how cholesterol metabolism via the LDLR receptor shapes risk across microsatellite-stable (MSS) versus microsatellite-unstable (MSI) tumors, and how the inflammatory enzyme PTGS2 (COX-2) operates within the tumor stroma through the WNT/APC signaling axis. The most compelling early signal is that the causal influence of these pathways appears to be highly context-dependent: genetic instruments for LDLR and PTGS2 seem to shift in direction and magnitude depending on tumor microsatellite status, stromal infiltration, and driver mutation background. This suggests that earlier conflicting results may have been obscured by studying biologically distinct cancers as if they were one.\n\nColorectal cancer is increasingly understood as a constellation of subtypes. MSI tumors often have defective DNA repair and immune-rich environments; MSS tumors typically display different metabolic and stromal features. Meanwhile, LDLR governs cholesterol uptake, and PTGS2 drives inflammation—both are well-known, druggable targets. But asking whether “LDLR causes CRC” or “PTGS2 causes CRC” is too blunt. The sharper question is: in which tissue, in which cell type, and under which molecular conditions? Answering that requires genetic variants that alter gene or protein levels in specific contexts—liver, colon epithelium, cancer-associated fibroblasts, or macrophages—and that reliably overlap with disease associations from large, multi-ancestry cohorts where tumors have been stratified by MSS/MSI status.\n\nTo interrogate this, the swarm executed three parallel pulls. First, it curated genetic variants tied to LDLR expression and protein abundance in liver and colon, then began testing whether their effect on CRC risk is modified by inherited tendencies toward obesity or dyslipidemia. Second, it extracted cell-type-specific expression variants for PTGS2 from colon, tumor bulk, and single-cell atlases of fibroblasts and macrophages, cross-referencing them against MSS/MSI-stratified genome-wide association data from GECCO, CORECT, FinnGen, and UK Biobank. Third, it analyzed CRISPR gene-editing co-dependency screens from cancer cell lines, calculating how disrupting LDLR-metabolic genes or PTGS2-WNT axis genes alters cell fitness when conditioned on MSI status, chromosomal instability, and mutations in APC, KRAS, or TP53.\n\nThese foundational scans produced one new finding this tick and refined five hypotheses, though no hardened causal edges have yet met the mission’s strict validation threshold—our knowledge base currently holds 154 entities but zero confirmed relations. The curated instrument sets suggest that liver-specific LDLR signals may colocalize with MSS-specific risk loci in ways that warrant deeper investigation, and that PTGS2 dependencies in stromal cells may only emerge when tumors are microsatellite-stable or harbor intact APC signaling. The CRISPR conditioning further indicates that metabolic and WNT-axis co-dependencies are subtype-specific, with effect directions that appear to reverse across MSI versus chromosomally unstable backgrounds. All of these patterns remain provisional and require rigorous experimental validation.\n\nThe urgent open questions are whether these expression-to-disease overlaps survive a high statistical threshold for shared genetic drivers across multiple ancestries; whether stromal-infiltration-stratified causal estimates replicate in independent tumor expression data from TCGA; and whether the CRISPR co-dependencies hold in MSI-high models that better recapitulate the stromal microenvironment. Next tick, the swarm will advance its strongest curated instruments through hardened-edge criteria, permanently archive off-target clinical literature, and withhold rare-variant hypotheses until at least one causal relation is locked. If these conditional signals hold, they could reveal precisely which CRC subtypes might benefit from metabolic or anti-inflammatory therapies.\n\n*These findings are generated by an AI swarm scanning published literature and should not be interpreted as medical advice. All candidates require experimental validation.*",
  "items_processed": 120,
  "findings": 1,
  "hypotheses": 5
}